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ABSTRACT:
Pancreatic carcinoma is one of the cancers with the worse prognosis, thus any 
therapeutic improvement is imperative. Cytotoxic LH-RH analog, AN-152 (proprietary 
designation, AEZS-108), consisting of doxorubicin (DOX) conjugated to D-Lys6LH-RH, 
is now in clinical trials for targeted therapy of several sex hormone-dependent tumors 
that express LH-RH receptors. We investigated LH-RH receptors in human pancreatic 
carcinoma and the effects of AN-152 (AEZS-108) on experimental pancreatic cancers. 
We determined LH-RH receptor presence in human pancreatic cancer samples by 
immunohistochemistry and, in three human pancreatic cancer lines (SW-1990, Panc-1 
and CFPAC-1), by binding assays and Western blotting. The effects of the cytotoxic 
LH-RH analog were investigated on growth of these same cancer lines xenografted 
into nude mice. We also analyzed differences between the antitumor effects of the 
cytotoxic analog and its cytotoxic radical alone, doxorubicin (DOX), on the expression 
of cancer-related genes by PCR arrays. LH-RH receptors were expressed in two 
randomly selected surgically removed human pancreatic cancer samples and in all 
three cancer lines. Cytotoxic LH-RH analogs powerfully inhibited growth of all three 
tumor lines in nude mice; AN-152 was significantly stronger than DOX on Panc-1 and 
CFPAC-1 cancers. PCR array showed that cytotoxic LH-RH analog AN-152 affected 
the expression of genes associated with cellular migration, invasion, metastasis and 
angiogenesis more favorably than DOX, however the changes in gene expression 
varied considerably among the three cancer lines. Cytotoxic LH-RH analog, AEZS-
108, may be a useful agent for the treatment of LH-RH receptor positive advanced 
pancreatic carcinoma. 
INTRODUCTION
Pancreatic carcinoma is the 9th most common human 
cancer in the Western world, including the USA, but it 
is the fourth leading cause of cancer death in both males 
and females. [1] Its incidence has increased in the white 
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population by about 1% per year between 1999 through 
2008. [2] Ductal carcinomas of the pancreas are very 
aggressive tumors, and because of the concealed location 
of the gland, they are mostly detected in late stages of 
development when surgical removal is not useful. Thus, 
the 5-year survival rate is below 5% and the median 
survival time after diagnosis is less than 6 months. [3] 
There is not an accepted uniform standard therapy around 
the world for pancreatic carcinoma; treatment methods 
vary by location and economic circumstances. [4] Current 
treatment modalities such as gemcitabine alone or in 
combination with 5-fluorouracil, radiation or erlotinib, 
(an EGF receptor tyrosine kinase inhibitor), provide 
minimal palliation for patients with advanced pancreatic 
cancers; latest reviews from around the world express 
overall disappointment with these results. [5-8] Recent 
trials showed that a combination regimen, FOLFIRINOX 
(5-fluorouracil, leucovorin, irinotecan and oxiplatin), 
showed superiority to gemcitabine monotherapy, but 
the combination is highly toxic and is recommended 
only for fit patients. [9-11] On the other hand, most 
publications express the opinion, so far justified, that the 
rapidly growing body of information on the molecular 
pathogenesis of pancreatic cancer will provide new 
therapeutic approaches for these patients. Because of 
the poor survival rates and the low response rates to 
chemotherapy, the NCI suggests that “Clinical trials are 
appropriate alternatives for treatment of patients with 
any stage of disease and should be considered prior to 
selecting palliative approaches”. [12]
One possible way to increase the efficacy of therapy 
is to target drugs to specific molecular components in 
cancer cells, such as growth factors and their receptors, 
or proliferation-promoting kinases etc. [13-16] Specific 
receptors for hypothalamic peptide hormones, including 
LH-RH, somatostatin and bombesin have been detected 
in various cancers, and these receptors may serve as 
targets for the peptide ligand linked to a cytotoxic agent. 
[13, 15, 17-21] Thus we have developed new classes of 
targeted antitumor agents by linking doxorubicin (DOX), 
or its derivative, 2-pyrrolino-DOX (AN-201), to LH-
RH, somatostatin and bombesin. Since these cytotoxic 
compounds are targeted to receptors for these specific 
hormones on tumor cells, the concentration of the toxic 
agent in tumor tissue is increased and normal cells are 
spared from exposure to toxicity. We demonstrated that in 
animal models, cytotoxic analogs of LH-RH, somatostatin 
and bombesin may each have very powerful inhibitory 
effects on cancers that express the corresponding receptors 
for the carrier peptide; these hybrid compounds are more 
effective and less toxic than the cytotoxic radicals alone. 
[13, 15, 21]
Based on information that receptors for somatostatin 
and bombesin are expressed in pancreatic cancers we 
tested the effects of cytotoxic analogs of somatostatin 
(AN-238) and bombesin (AN-215) on human pancreatic 
cancer lines xenografted into nude mice. AN-238 and 
AN-215 significantly inhibited growth of SW-1990, 
Panc-1, CFPAC-1, Capan-1 and Capan-2 tumors each 
of which expresses various subtypes of somatostatin 
receptors and bombesin receptors. [22, 23] LH-RH and 
its receptor are not confined to the hypothalamic-pituitary 
axis. [24] In the periphery, the LH-RH system coordinates 
gonadal functions and serves as a growth factor of benign 
conditions [25-28] and various malignancies. [29, 30] 
Following our first demonstration of LH-RH receptors 
Figure1: Expression of LH-RH receptors in human pancreatic cancer. Sections of two randomly selected carcinomas were 
stained with hematoxylin-eosin (a and c) and LH-RH receptors were detected in parallel sections with immunohistochemistry as described 
in the Materials and Methods. The receptors appear in brown in the cancerous glandular epithelia (b and d).
a b 
c d 
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in pancreatic cancers in 1989, several other groups 
have confirmed that receptors for LH-RH are present in 
pancreatic tumors [15, 21] Based on these findings, in 
the present study, we investigated the effects of cytotoxic 
LH-RH analog AN-152 (AEZS-108), consisting of 
[D-Lys6]LH-RH linked to DOX-14-O-hemiglutarate on 
various human pancreatic cancers in nude mice. [13] This 
analog has had strong inhibitory effects on experimental 
prostate, breast, ovarian, endometrial, renal and colorectal 
carcinomas, as well as non-Hodgkin’s lymphomas and 
melanomas. [13, 15, 21] AN-152 (AEZS-108), is now in 
phase I/II and III clinical trials for the treatment of human 
ovarian, endometrial, prostate and bladder cancers. [31]
RESULTS
LH-RH receptor expression in clinical pancreatic 
cancer specimens and in human cancer lines
Immunohistochemical investigation verified the 
expression of LH-RH receptors in two randomly selected 
archived samples of surgically removed human pancreatic 
cancers (Fig. 1). Positive staining was observed in the 
malignant epithelial cells, but not in stromal elements or 
peritumoral tissues. 
In untreated samples of the three human pancreatic 
cancer lines, high affinity and low capacity LH-RH 
receptors were detected. The dissociation constants and 
maximal binding capacities of the receptors were as 
follows: SW-1990: Kd= 4.51±0.51 nM, Bmax=624.3±24.3 
fmol/mg protein; Panc-1: Kd=6.27±0.08 nM, 
Bmax=495.3±17.4 fmol/mg membrane protein; CFPAC-1: 
Kd=3.89±0.12 nM, Bmax=306.0±27.5 fmol/mg protein.
LH-RH receptor protein (38 kD), detected with 
Western blotting, was present in all three tumor lines; 
the amount of this protein was not significantly different 
between treated and control samples (Fig. 2)
 Earlier binding studies demonstrated moderate-
affinity binding sites for LH-RH also in nitrosamine-
induced pancreatic cancers in hamsters (13).
Effect of treatment on tumor growth in nude mice
In Experiment 1, AN-152 powerfully inhibited 
growth of Panc-1 cancers in nude mice, while DOX had 
only a moderate but not significant inhibitory effect (Fig. 
3, Table 1). Neither treatment had an effect on body and 
organ weights of the mice. 
In Experiment 2, cysts containing clear yellowish 
or brownish liquid developed in many tumors SW-1990 
starting on treatment day 30. These cysts grew very 
rapidly, making tumor volume results non-germane. Thus 
the volumes of macroscopically cystic and non-cystic 
tumors were calculated separately. Similarly, at autopsy, 
the cystic tumors were weighed, the tumors cut, and the 
fluid released, and the solid parts weighed again. Tumor 
volume changes are shown in Figure 3, the numerical data 
are shown in Table 1. Tumor volume was significantly 
lower in both groups treated with cytotoxic compounds. 
Weights of cystic tumor were significantly reduced by 
treatment with AN-152 and solid tumor weights were 
reduced by AN-152 and DOX.  Weight ratio of cystic 
versus solid tumors was highest in the groups receiving 
AN-152 showing that the fluid amount was significantly 
larger in this group than in the other groups. Body 
weights and weights of livers, kidneys and ovaries were 
significantly lower in the groups receiving cytotoxic 
Table 1: Effect of treatment with cytotoxic LH-RH analog AN-152 on volume and 
weights of human  pancreatic cancers in nude mice
Experiments/Groups Tumor volume 
(final) (mm3)
Tumor weights (mg)
Panc-1
Control 2040±1357 606±340d
AN-152 183±76a 93±161a
DOX 849±363 689±139
2.  SW-1990 Tumors with cysts       Solid tumor part     Cystic/solid  tumor 
Control 3464±838 3729±921                         2473±636                  1.56±0.12
AN-152 919±248a 1160±288a                        371±69a                     2.58±0.42b
DOX 1213±381a 1496±466                         585±141a                   1.93±0.30
4. D-Trp6[LH-RH] 2791±646 3107±696                        1862±361                   1.56±0.11
3.CFPAC-1
Control 2502±769 518±244c
AN-152 338±81a 360±102
DOX 1063±518 540±140
Values are means ± SE      aP<0.05 vs. Control   bP<0.05 vs. all other groups      cSome tumors in these 
experiments contained cysts and were weighed after cysts were cut and fluid released. 
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compounds but not in those treated with D-Trp6LH-RH.
In Experiment 3, volume changes of CFPAC-1 
tumors are shown in Figure 3 and numerical data are 
shown in Table 1. Tumor volume was significantly lower 
in the groups treated with AN-152.  Treatment with DOX 
resulted in a moderate but not significant decrease in 
tumor volume. Tumor weights were also reduced after 
treatment with AN-152, but the differences from control 
were statistically not significant. Body weights were the 
lowest in the group receiving DOX, but the differences 
from control were statistically not significant. Organ 
weights were not changed by the treatments, except for 
ovarian weights, which were reduced by DOX. 
Gene expression analysis
To discover differences in the effects of AN-152 
and DOX on molecules important in cancer development 
and progression, the Human Cancer Pathway Finder PCR 
Array was used. The expression of genes in the treated 
tumors compared to controls is shown in Fig. 4A,B. 
Among the genes related to invasion and metastasis, both 
decreases and increases in expression were observed in 
all three tumor lines, with DOX causing the stronger 
increases. Expression of angiogenesis-related genes varied 
in different directions in the three tumors; mostly increases 
were seen in Panc-1 and SW-1990 while mostly decreases, 
in CFPAC-1. The decreases were caused mostly by AN-
152 and the increases by DOX. Expression of genes 
associated with adhesion was decreased in Panc-1 and 
CFPAC-1 cancers by both compounds, somewhat more 
strongly by AN-152, and were changed in both directions 
by both agents in SW-1990 tumors (all Fig. 4A). Both AN-
152 and DOX caused changes in expression of the genes 
related to signal transduction molecules and transcription 
factors; DOX caused considerable increases or decreases 
in some. Increases and decreases in expression of 
apoptosis-associated genes were variable in the three 
tumors after both treatments. The genes associated with 
cell cycle control and DNA damage repair were altered 
in both directions in Panc-1 and SW-1990 cancers, and 
showed only decreases in CFPAC-1 cancers (all Fig. 4B). 
To analyze the effects of AN-152 and DOX on 
expression of apoptosis-related genes, the Human 
Apoptosis RT Profiler PCR Array was used. Among the 
pro-apoptotic genes investigated, several were increased 
in Panc-1 and decreased in CFPAC-1 cancers, but were 
changed in both directions in SW-1990 (Fig. 5A). Thus, 
the expression of anti-apoptotic genes was mostly 
increased in Panc-1 and SW-1990 and decreased in 
CFPAC-1 tumors, similarly by both agents (Fig. 5B). 
Figure2: LH-RH receptor protein (38 kD) was detected 
by Western blotting in three human pancreatic cancer 
lines grown in nude mice. Representative blots of three 
independent experiments are shown. The lower right corner 
shows proteins from 3T3 cells as negative control.
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Figure3: Effect of treatment with cytotoxic LH-RH 
analog, AN-152 (AEZS-108), and its cytotoxic radicals, 
doxorubicin (DOX), on growth of human pancreatic 
cancers in nude mice. The vertical bars represent SE. Arrows 
show days of treatment.
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DISCUSSION
Recent advances in understanding the molecular 
mechanisms involved in the genesis and progression 
of pancreatic cancer have provided us with novel 
therapeutic approaches. Among the new modalities, 
which have become commercially available, some target 
growth factors and their receptors, (e.g. EGF or PDGF) 
and intracellular kinases (e.g. protein kinase C), and 
some target pro-angiogenic molecules (e.g. VEGF or 
interleukin-8). [14, 32-34] 
Receptors for various peptide hormones are 
present in pancreatic cancers and these receptors can be 
utilized for both diagnostic and therapeutic purposes. 
[15, 21]. LH-RH receptors in experimental and human 
pancreatic tumors were demonstrated long ago. [15, 21] 
however, their function and importance is still unclear. 
The combined detection of mRNA for both LH-RH and 
LH-RH receptor in rat pancreatic cancer lines raised the 
possibility of an autocrine/paracrine role of LH-RH in 
these tumors. [35] The findings that both estrogen and 
androgen receptors are likewise expressed in pancreatic 
carcinoma indicate that sex steroids may also play a role 
in the growth of these tumors. We have shown in several 
experiments that treatment with an LH-RH agonist, 
D-Trp6LH-RH, or antagonist, cetrorelix, inhibits growth 
of nitrosamine-induced pancreatic cancers in hamsters. 
[15, 21] This inhibition can be the result of the blockade 
of the pituitary-gonadal axis or of a direct effect through 
LH-RH receptors in tumors. Unfortunately, clinical trials 
with LH-RH agonists have had disappointing results in 
pancreatic cancer patients. [15, 21] The actual mechanism 
of action of cytotoxic LH-RH analogs differs from those 
of hormone agonists or antagonists however, as in this 
situation the hormone performs only a delivery role, 
carrying the cytotoxic moiety to tumor cells that express 
specific receptors for that hormone. Thus, AN-152 (AEZS-
108) acts primarily as a cytotoxic molecule targeted to 
tumor cells rather than as a hormonal agent. The inhibitory 
effect of AN-152 (AEZS-108) on two pancreatic cancer 
lines was recently demonstrated by others. [36]
In the present study we demonstrated the presence 
of LH-RH receptors in clinical pancreatic cancer 
samples as well as in three human pancreatic cancer cell 
lines. Cytotoxic LH-RH analog, AN-152 (AEZS-108) 
powerfully inhibited growth of all three of these lines 
xenografted into nude mice. DOX alone also had an 
inhibitory effect on growth of SW-1990 tumors, but AN-
152 acted significantly more strongly than DOX on Panc-1 
and CFPAC-1 tumors. 
In previous studies, various other of our cytotoxic 
conjugates, such as cytotoxic analog of LH-RH (AN-
207), somatostatin (AN-238) and bombesin (AN-215), 
powerfully inhibited growth in nude mice of human 
pancreatic cancer lines that expressed the specific 
receptors for those carrier peptides (17, 18). Herein, 
we demonstrated that cytotoxic LH-RH analog, AN-
152 (AEZS-108), also has a strong inhibitory effect on 
experimental pancreatic cancers. 
PCR arrays have been successfully used in our 
previous studies to detect molecular changes elucidating 
the effects of our antineoplastic compounds. [37-39] 
Using the PCR array method in the present study, we 
also discovered some differences between the effects of 
the cytotoxic hormone analog and the cytotoxic radical 
moiety. The genes which were investigated encode 
proteins that are involved in various biological pathways 
important in tumorigenesis and tumor progression. The 
changes were each relatively modest, probably because 
the animals were sacrificed on the average of 3 weeks 
after the last injection. Small changes add up however, as 
many genes were affected. Differences between the effects 
of AN-152 and the DOX moiety were demonstrated 
mainly in genes associated with invasion and metastasis, 
adhesion and angiogenesis. AN-152 affected MMP-
related genes more markedly than DOX; however, DOX 
strongly increased TIMP3, which is an MMP inhibitor. 
Metalloproteinases are responsible for extracellular matrix 
and basement membrane degradation in tumors and thus 
have a major role in invasion and metastasis. MMP1, 
MMP2 and MMP9, as well as their inhibitors, TIMP1 
and TIMP2, were detected in pancreatic cancers, and their 
concentrations correlated with tumor grade, tumor size, 
invasive characteristics, and metastasis. [40-42] Drugs 
that inhibit the activity of MMPs in cancer progression 
have been sought, developed and tested clinically, thus 
the ability of AN-152 to decrease MMP levels may be an 
important factor in its mechanism of tumor inhibition, and 
its efficacy.
Both AN-152 and DOX decreased expression of 
genes connected to adhesion in Panc-1 and CFPAC-1 
tumors, with AN-152 having a slightly stronger effect. In 
CFPAC-1 cancers, angiogenesis-related gene expression 
was strongly decreased by AN-152 and strongly increased 
by DOX. There was no major difference in the effects of 
AN-152 and DOX on other gene expression categories, 
including apoptosis-related genes. Consequently, it 
is obvious that these effects depend not only on the 
compounds used for therapy, but also on the type of 
tumor. Thus, it is understandable that in these experiments 
with pancreatic tumors the two compounds similarly 
affected genes associated with apoptosis, while they acted 
differently on these same genes in bladder cancers [43] or 
glioblastomas [44] in other experiments. 
Summarizing the results of our study, we can 
state that receptors for LH-RH are expressed in human 
pancreatic cancers, and that receptor-targeted therapy 
with the cytotoxic LH-RH analog, AN-152 (AEZS-
108), has a stronger inhibitory effect on the growth of 
human pancreatic cancer lines in nude mice than the 
cytotoxic radical, DOX. In SW-1990 cancers, where 
LH-RH receptor expression seemed to be the lowest, the 
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difference between the effects of the two compounds was 
the least.  Because of the poor response to conventional 
chemotherapy, radiation therapy, and surgery, patients 
with any stage of pancreatic cancer can appropriately be 
considered as candidates for clinical trials with this agent. 
Based on our results, AEZS-108 (AN-152) deserves to 
be tried for treatment of patients with LH-RH receptor 
positive pancreatic cancers.
MATERIALS AND METHODS
Ethics Statement
This investigation has been conducted in accordance 
with the ethical standards and according to the Declaration 
of Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board.
Detection of LH-RH receptors in human 
pancreatic cancer specimens
Two archived samples of surgical specimens 
of human pancreatic cancers were used for the 
immunohistochemical studies. These were formalin-fixed 
and paraffin-embedded.  Three micrometer thick sections 
were stained with hematoxylin and eosin to confirm the 
presence of pancreatic adenocarcinoma. Adjacent serial 
sections were then utilized for the immunoperoxidase 
procedure following standard protocol. Briefly, the 
slides were deparaffinized, rehydrated and washed in 
phosphate-buffered saline solution. Antigen retrieval was 
performed in a pressure cooker with Dako Target Retrieval 
Figure4: Human pancreatic cancer lines grown in nude mice were analyzed with the Human Cancer Pathway Finder 
RT Profiler PCR Array. The bars show fold changes compared to control. *= P<0.05 vs control. The genes are grouped according to 
their functions as follows. (A) Invasion and metastasis: TWIST1: Twist homolog 1; TIMP3: TIMP metallopeptidase inhibitor 1; SERPINE1: 
Serpine peptidase inhibitor, clade E, member 1; SERPINB5: Serpin peptidase inhibitor, clade B, member 5; PLAUR: Plasminogen activator, 
urokinase receptor; NME4, NME1: Non-metastatic cells protein 4, 1; MMP9, 2, 1: Matrix metallopeptidase 9, 2, 1. Angiogenesis: THBS1: 
Thrombospondin 1; TGFBR1: Transforming growth factor beta receptor 1; TEK: TEK tyrosine kinase; IL8: Interleukin 8; IGF1: Insulin-like 
growth factor 1; IFNB1: Interferon, beta 1; IFNA1: Interferon, alpha 1; FGFR2: Fibroblast growth factor receptor 2; COL18A1: Collagen, 
type XVIII, alpha 1; AGPT2, 1: Angiopoietin 2, 1. Adhesion: EPDR1: Ependymin related protein 1; SYK: Spleen tyrosine kinase; MCAM: 
Melanoma cell adhesion molecule; ITGB, ITGA: Integrin beta, alpha. (B) Signal transduction molecules and transcription factors: SNCG: 
Synuclein gamma (breast cancer specific protein); PIK3R1: Phosphoinositide-3-kinase, regulatory subunit 1; MAP2K1: Mitogen-activated 
protein kinase 1; ETS2: V-Ets erythroblastosis virus E26 oncogene homolog 2; AKT1: V-akt murine thymoma viral oncogene homolog 1. 
Apoptosis and cell senescence: TNFRSF25, 1A, 10B: Tumor necrosis factor receptor superfamily member 25, 1a, 10b; TERT: Telomerase 
reverse transcriptase; GZMA: Granzyme A; FAS: Fas (TNF receptor superfamily, member 6; CFLAR: CASP8 and FADD-like apoptosis 
regulator; CASP8: Caspase 8; BCL2L1: BCL2-like 1; BCL2: B-cell CLL/lymphoma 2. Cell cycle control and DNA damage repair: TP53: 
Tumor protein p53; RB1: Retinoblastoma 1; E2F1: E2F transcription factor 1; CDKN2A, 1A: Cyclin-dependent kinase inhibitor 2A, 1A; 
CDC25A: Cell division cycle 25 homolog A; BRCA1: Breast cancer 1; ATM: Ataxia telangiectasia mutated. 
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Solution (S1968; Dako, Carpinteria, CA) at 90˚C for 15 
min (pH 9.0). Antibodies to LH-RH receptor (NCL-
GnRHR A9E4;  Novocastra Laboratories Ltd, Newcastle 
upon Tyne , United Kingdom and GnRHR-N20, Santa 
Cruz Biotechnology, Santa Cruz, CA) were added and 
slides  incubated for 30 min at room temperature. NCL-
GnRHR is a monoclonal antibody raised in mouse and 
targets the human LH-RH receptor extracellular region. 
The GnRH-R N20 is an affinity-purified goat polyclonal 
antibody and maps near the N-terminus of human LH-
RH-R. Following the addition of the detection system, 
the reaction was visualized using diaminobenzidine. The 
slides were counterstained with hematoxylin. Human 
pituitary (anterior lobe), obtained from autopsy, was used 
as positive control.
Materials
LH-RH agonist [D-Lys6]LH-RH (pyroGlu-His-Trp-
Ser-Tyr-D-Lys-Arg-Pro-Gly-NH2) carrier was synthesized 
in our laboratory by solid-phase methods. DOX.HCl 
salt was purchased from Chemex Export-Import GmbH 
(Vienna, Austria). Cytotoxic LH-RH conjugate AN-152 
was synthesized by AEterna/Zentaris (Frankfurt am Main, 
Germany). Chemicals, unless stated otherwise, were 
purchased from Sigma (St. Louis, MO). For treatment, 
the cytotoxic compounds were dissolved in 0.01 M 
aqueous acetic acid and diluted with 5.5% (w/v) aqueous 
D-mannitol, and 0.2 ml/20 g body weight of this solution 
was injected into the jugular veins of the test mice.
Figure5: Human pancreatic cancer lines grown in nude mice were analyzed with the Human Apoptosis RT Profiler 
PCR Array as described in the Materials and Methods. The vertical bars show fold changes in gene expression compared 
to control. *= P<0.05 vs control. (A) Pro-apoptotic genes: TRAF3: TNF receptor-associated factor 3; TRADD: TNFRSF1A-assiciated 
via death domain; TP73: Tumor protein p73; TP53BP2: Tumor protein p53 binding protein 2; TP53: Tumor protein p53; TNFSF8, 10: 
Tumor necrosis factor superfamily, member 8, 10; TNFRSF10, 9 25, 21, 1A, 10A, 10B: Tumor necrosis factor receptor superfamily, 
member 10, 9, 25, 21, 1A, 10A, 10B; TNF: Tumor necrosis factor; RIPK2: Receptor-interacting serine-threonine kinase 2; PYCARD: PYD 
and CARD domain containing; NOD1: Nucleotide-binding oligomerization domain containing 1; NFKB1: Nuclear factor of kappa light 
polypeptide gene enhancer in B cells 1; LTBR: Lymphotoxin beta receptor; LTA: Lymphotoxin alpha; HRK: Harakiri, BCL2 interacting 
protein; GADD45A: Growth arrest and DNA-damage-inducible, alpha; FASLG: Fas ligand; FAS: Fas (TNF receptor superfamily, member 
6); FADD: Fas-associated via death domain; DIABLO: Diablo, IAP-binding mitochondrial protein; DFFA: DNA fragmentation factor; 
DAPK1: Death-associated protein kinase 1; CYCS: Cytochrome c, somatic; CRADD: CASP2 and RIPK1 domain containing adaptor with 
death domain; CIDEB, A: Cell death-inducing DFFA-like effector b, a; CD70, 40, 27: CD70, 40, 27 molecule; CASP: Caspase, apoptosis-
related cystine peptidase; BRAF: V-raf murine sarcoma viral oncogene homolog B1; BNIP3L: BCL2, adenovirus E1B 19kDa interacting 
protein 3-like; BIK: BCL2-interacting killer; BID: BH3 interacting domain death agonist; BCL2L11: BCL2-like 11; BCL10: B-cell CLL/
lymphoma 10; BAX: BCL2-associated X protein; BAK1: BCL2-antagonist/killer 1; BAD: BCL2-associated agonist of cell death; APAF1: 
Apoptotic peptidase activating factor 1; ABL1: C-abl oncogene 1. (B) XIAP: X-linked inhibitor of apoptosis; TRAF2: TNF receptor 
associated factor 2; TNFRSF1B, 11B: Tumor necrosis factor receptor superfamily member 1B, 11B; NOL3: Nucleolar protein 3; NAIP: 
NLR family, apoptosis inhibitory protein; MCL1: Myeloid cell leukemia sequence 1; IL10: Interleukin 10; IGF1R: Insulin-like growth 
factor 1 receptor; CFLAR: CASP8 and FADD-like apoptosis regulator; CD40LG: CD40 ligand; BNIP2: BCL2/adenovirus E1B 19kDa 
interacting protein 2; BIRC6, 5, 3, 2: Baculoviral IAP repeat containing 6, 5, 3, 2; BFAR: Bifunctional apoptosis regulator; BCL2L2, 10, 
1, A1: BCL2-like…; BCL2: B-cell CLL/lymphoma 2; BAG3, 1: BCL2-associated athanogene 3, 1; AKT1: V-akt murine thymoma viral 
oncogene homolog 1; AIFM1: Apoptosis-inducing factor, mitochondrium-associated, 1. 
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TRADD
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TP53BP2
TP53
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TNFRSF9
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CD40
CD27
CASP9
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CASP7
CASP6
CASP5
CASP4
CASP3
CASP2
CASP14
CASP10
CASP1
BRAF
BNIP3L
BNIP3
CASP4
CASP3
CASP2
CASP14
CASP10
CASP1
BRAF
BNIP3L
BNIP3
BIK
BID
BCL2L11
BCL10
BAX
BAK1
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APAF1
ABL1
BIK
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BAK1
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ABL1
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Anti-apoptotic genes
Panc-1 SW-1990 CFPAC-1
XIAP
TRAF2
TNFRSF1B
TNFRSF11B
NOL3
NAIP
MCL1
IL10
IGF1R
XIAP
TRAF2
TNFRSF1B
TNFRSF11B
NOL3
NAIP
MCL1
IL10
IGF1R
CFLAR
CD40LG
BNIP2
BIRC6
BIRC5
BIRC3
BIRC2
BFAR
BCL2L2
CFLAR
CD40LG
BNIP2
BIRC6
BIRC5
BIRC3
BIRC2
BFAR
BCL2L2
BCL2L10
BCL2L1
BCL2A1
BCL2
BAG3
BAG1
AKT1
AIFM1
BCL2L10
BCL2L1
BCL2A1
BCL2
BAG3
BAG1
AKT1
AIFM1
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Animals and Tumors
Female athymic nude mice (Ncr nu/nu) were 
obtained from the National Cancer Institute (Frederick 
Cancer Research and Development Center, Frederick, 
MD), Charles River Laboratories International, Inc. 
(Durham, NC) and Harlan Laboratories (Tampa, FL) 
and maintained under pathogen-limited conditions. SW-
1990, Panc-1 and CAPAN-1cells were purchased from 
the American Type Culture Collection (ATCC; Manassas, 
VA) and maintained in culture according to ATCC’s 
recommendation. To produce tumor donor animals, 106 
cells of each line were injected subcutaneously into 3 nude 
mice and grown until well-developed tumors were grown. 
The resulting tumors were removed, minced and 2 mm3 
pieces of tumor tissue were transplanted subcutaneously 
into each flank area of the experimental nude mice. When 
the tumors became measurable, the mice were divided into 
groups with nearly equal average tumor sizes. Control and 
treatment groups were then selected at random.
Experimental protocol
In Experiment 1, nude mice with Panc-1 tumors 
were treated iv. on days 1, 8. 15, 22, 33 and 61 as follows: 
Group 1: Control (vehicle only); Group 2: AN-152, 6.9 
µmol/kg; Group 3, DOX, 2.5 µmol/kg. There were 8 
animals in each group. The experiment was terminated on 
day 82. 
In Experiment 2, the treatment of mice with SW-
1990 cancers started 33 days after implantation as 
follows: Group 1: Control; Group 2: AN-152; Group 3: 
DOX, Group 4: D-Trp6[LH-RH]. All compounds were 
administered iv.(at 6.9 µmol/kg) once weekly for 7 weeks. 
There were 10 animals per group. The experiment was 
terminated 65 days after the first treatment. 
In experiment 3, the treatment started 87 days after 
implantation of CFPAC-1 cancers as follows: Group 
1: Control; Group 2: AN-152; Group 3: DOX. The 
compounds were given iv. on days 1, 5, 8, 12, 15 and 30. 
There were 8 animals per group, and the experiment lasted 
to the 61st day of the treatment period.
Receptor binding assay
LH-RH receptors were analyzed by the binding 
of 125I-labeled [D-Trp6]LH-RH to tumor membrane 
homogenates of control animals as described. [45] Four 
analyses were done in all samples in duplicate or triplicate 
tubes and binding characteristics were acquired from 
12-point displacement experiments. The LIGAND PC 
computerized curve-fitting program was used to determine 
the type of binding, the maximal binding capacity of the 
receptors and the dissociation constant (31). 
Molecular analysis
After isolating total RNA and protein from tumor 
samples from experiments 2, 3 and 4 by using the 
NucleoSpin kit (Macherey-Nagel, Bethlehem, PA, USA), 
the Human Cancer Pathway Finder Superarray and the 
Human Apoptosis RT Profiler PCR Array (Qiagen Inc. 
Valencia, CA, USA) were used to analyze 3 representative 
samples from each group for mRNA levels of genes related 
to cell adhesion, apoptosis, cell cycle, angiogenesis, signal 
transduction, invasion and metastasis. Quality control of 
RNA samples, synthesis of cDNA and RT-PCR arrays 
were performed as described. [46] Gene expression 
data were examined using Excel based PCR Array Data 
Analysis Software provided by Qiagen; fold-changes in 
gene expression were calculated using the ΔΔCt method 
and five housekeeping genes (B2M, HPRT1, RPL13A, 
GAPDH, and ACTB) were used for normalization of the 
results.
The proteins isolated from three tumor samples 
in Experiments 2, 3 and 4 were processed for Western 
blotting to detect expression of LH-RH receptors as 
described. [47] Briefly, isolated proteins were sonicated 
and the lysates were adjusted to equal concentrations. 
Primary antibodies for LH-RH receptor were purchased 
from Abcam (ab-58561; Cambridge, MA, USA).  The 
immunoreactive bands were visualized with the Odyssey 
Infrared Imaging System, and 3.0 software was used (LI-
COR Biosciences, Lincoln, NE, USA). 
Statistical analysis
One-way ANOVA (Sigmaplot-11 software; Jandel 
Scientific, San Raphael, CA) was used for statistical 
evaluation of the data, and the groups were compared 
using Dunnett’s method.
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